The Growing Strategic Importance Of CDMOs In Cell & Gene Therapy

Cell and gene therapies (CGTs) are becoming increasingly important across healthcare, particularly in oncology, cardiovascular, and CNS diseases. Despite continued regulatory momentum and growing commercial potential, the industry still faces major manufacturing challenges, including limited infrastructure, analytical bottlenecks, supply chain complexity, and slow production timelines. As demand shifts from basic capacity to advanced capability, CDMOs are expected to deliver scalable manufacturing platforms, accelerated tech transfer, AI-driven automation, and integrated analytical and logistics support.

Catalent addresses these evolving needs through end-to-end CGT development and manufacturing solutions, from CMC strategy and regulatory alignment to clinical and commercial-scale production. Its scalable AAV platform, accelerated timelines, and integrated draw-to-infusion logistics capabilities help customers streamline development, reduce late-stage risk, and support the growing complexity of autologous cell therapies. As CGTs continue to evolve, success will increasingly depend on agile CDMO partnerships that combine technical expertise, operational flexibility, and long-term strategic support.